SCHEMBL2823686

SCHEMBL2823686

CCOC(=O)c1sc(-c2ccc([N+](=O)[O-])cc2)nc1C

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.70
CDC7 O00311 6/20 0.67
DBF4 Q9UBU7 6/20 0.67
PTPN11 Q06124 1/20 0.64
GAA P10253 1/20 0.63
TRPM8 Q7Z2W7 4/20 0.56
KDM4E B2RXH2 2/20 0.54
MAPT P10636 2/20 0.54
ALDH1A1 P00352 1/20 0.54
PPARA Q07869 1/20 0.53
LMNA P02545 1/20 0.53
MEN1 O00255 1/20 0.51
HSP90AA1 P07900 1/20 0.51
CRHBP P24387 1/20 0.51
KMT2A Q03164 1/20 0.51
CRHR2 Q13324 1/20 0.51
AR P10275 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28295554 0.89 RAB9A (0.66) RAB9ACDC7DBF4PTPN11GAA
SCHEMBL15176802 0.85 CDC7 (0.70) RAB9ACDC7DBF4PTPN11GAA
SCHEMBL892889 0.84 CDC7 (0.77) RAB9ACDC7DBF4GAATRPM8
SCHEMBL4764983 0.84 RAB9A (0.58) RAB9ACDC7DBF4PTPN11GAA
SCHEMBL290384 0.83 CDC7 (0.75) RAB9ACDC7DBF4PTPN11GAA
SCHEMBL8867718 0.83 RAB9A (1.00) RAB9AGAAKDM4EMAPTALDH1A1
SCHEMBL460614 0.82 CDC7 (0.57) RAB9ACDC7DBF4PTPN11TRPM8
SCHEMBL2885887 0.82 TRPM8 (0.78) RAB9ACDC7DBF4TRPM8KDM4E
SCHEMBL289229 0.82 CDC7 (0.73) RAB9ACDC7DBF4GAATRPM8
SCHEMBL2085303 0.82 CDC7 (0.73) RAB9ACDC7DBF4PTPN11GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116585297-A Application of sulfonamide derivative 云南大学附属医院 2023-08-15 CN disclosed
CN-109810071-A A kind of miRNA biosynthesis inhibitor 中国科学院成都生物研究所 2019-05-28 CN disclosed
EP-2226322-B1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO CO LTD (JP) 2015-01-21 EP disclosed
US-8927588-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-06 US disclosed
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
US-8536197-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-17 US disclosed
US-20110160192-A1 BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS SPIROGEN LIMITED (GB) 2011-06-30 US disclosed
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-12-09 US disclosed
EP-2226322-A1 IMIDAZOLE CARBONYL COMPOUND Daiichi Sankyo Company, Limited (JP) 2010-09-08 EP disclosed
US-20070249591-A1 Biaryl Amino Acids and Their Use in Dna Binding Oligomers SPIROGEN LIMITED (GB) 2007-10-25 US disclosed
US-20070249591-A1 Biaryl Amino Acids and Their Use in Dna Binding Oligomers SPIROGEN LIMITED (GB) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160192-A1 BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS PCNA, POLL, XPA RAB9A 3598/4885CDC7 1328/4885DBF4 1051/4885
US-20070249591-A1 Biaryl Amino Acids and Their Use in Dna Binding Oligomers PCNA, POLL, DNA2 RAB9A 3625/4885CDC7 1291/4885DBF4 1136/4885
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A RAB9A 2042/4885CDC7 271/4885DBF4 1344/4885
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A RAB9A 2487/4885CDC7 726/4885DBF4 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.